Volume 2 Supplement 1
Current trends in leukemia, lymphoma, myeloma and ITP: updates and highlights from ASH 2008
Meeting abstracts
Edited by Delong Liu
Current trends in leukemia, lymphoma and myeloma.
White Plains, NY, USA31 January 2009
-
Citation: Journal of Hematology & Oncology 2009 2(Suppl 1):I1
-
Molecular target therapy – towards curative regimen: a 20-year experience in the treatment of acute promyelocytic leukemia (APL) in the Shanghai Institute of Hematology
Citation: Journal of Hematology & Oncology 2009 2(Suppl 1):A1 -
Update of recent studies in chronic myeloid leukemia
Citation: Journal of Hematology & Oncology 2009 2(Suppl 1):A2 -
New insights on low-grade and T-cell lymphoma
Citation: Journal of Hematology & Oncology 2009 2(Suppl 1):A3 -
Recent progress in the treatment of multiple myeloma: updates and highlights from ASH 2008
Citation: Journal of Hematology & Oncology 2009 2(Suppl 1):A4 -
Update on chronic immune thrombocytopenic purpura (ITP)
Citation: Journal of Hematology & Oncology 2009 2(Suppl 1):A5
-
Official journal of
-
Journal of Hematology & Oncology is the official journal of the Chinese American Hematologist and Oncologist Network.
-
- Editorial Board
- Manuscript editing services
- Instructions for Editors
- Instructions for authors
- Sign up for article alerts and news from this journal
Follow
Annual Journal Metrics
-
Citation Impact 2023
Journal Impact Factor: 29.9
5-year Journal Impact Factor: 27.1
Source Normalized Impact per Paper (SNIP): 4.489
SCImago Journal Rank (SJR): 7.522Speed 2024
Submission to first editorial decision (median days): 4
Submission to acceptance (median days): 61Usage 2024
Downloads: 3,430,659
Altmetric mentions: 1,308
Institutional membership
Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).
Funding your APC
​​​​​​​
​​
​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here.